
  
    
      
        Introduction_NNP
        Dietary_NNP and_CC lifestyle_NN changes_NNS during_IN the_DT last_JJ century_NN have_VBP entailed_VBN an_DT unprecedented_JJ
        epidemic_NN of_IN obesity_NN and_CC associated_VBN metabolic_JJ diseases_NNS ,_, including_VBG type_NN 2_CD diabetes_NN and_CC
        atherosclerosis_NNS [_NN 1_CD ]_NN ._. Many_JJ individuals_NNS suffer_VBP simultaneously_RB from_IN more_JJR than_IN one_CD of_IN these_DT
        conditions_NNS ,_, and_CC epidemiological_JJ studies_NNS in_IN humans_NNS ,_, as_RB well_RB as_IN studies_NNS in_IN animal_NN models_NNS ,_,
        suggest_VBP that_IN obesity-related_JJ insulin_NN resistance_NN is_VBZ a_DT common_JJ pathogenic_JJ feature_NN [_NN 2_CD ]_NN ._. Indeed_RB ,_,
        insulin_NN resistance_NN is_VBZ the_DT keystone_NN of_IN the_DT “ metabolic_JJ syndrome_NN ,_,” a_DT major_JJ cardiovascular_JJ risk_NN
        factor_NN even_RB in_IN the_DT absence_NN of_IN demonstrable_JJ glucose_NN intolerance_NN or_CC diabetes_NN [_NN 3_CD ]_NN ._. Obesity_NNP and_CC
        insulin_NN resistance_NN are_VBP strongly_RB associated_VBN with_IN systemic_JJ markers_NNS of_IN inflammation_NN ,_, and_CC ,_,
        indeed_RB ,_, inflammation_NN may_MD contribute_VB to_TO insulin_NN resistance_NN [_NN 4_CD ]_NN ._. Similarities_NNP and_CC overlap_VB
        between_IN obesity_NN and_CC inflammatory_JJ states_NNS are_VBP emerging_VBG ._. Inflammatory_NNP cytokines_NNS such_JJ as_IN tumor_NN
        necrosis_NNS factor_NN α_NN (_( TNF_NNP α_NN )_) and_CC interleukin_NN (_( IL_NNP )_) -_: 6_CD are_VBP produced_VBN by_IN adipocytes_NNS as_RB well_RB as_IN by_IN
        monocytes_NNS and_CC macrophages_NNS ,_, and_CC they_PRP circulate_VBP at_IN increased_VBN levels_NNS in_IN individuals_NNS with_IN
        obesity_NN [_NN 5_CD ,_, 6_CD ]_NN ._. Moreover_RB ,_, bone-marrow-derived_JJ macrophages_NNS home_NN in_IN on_IN adipose_NN tissue_NN in_IN
        individuals_NNS with_IN obesity_NN [_NN 7_CD ,_, 8_CD ]_NN ,_, and_CC adipocytes_NNS and_CC macrophages_NNS may_MD even_RB be_VB interconvertible_JJ
        [_NN 9_CD ]_NN ._. Furthermore_RB ,_, inflammation_NN is_VBZ increasingly_RB recognized_VBN as_IN a_DT major_JJ component_NN and_CC
        predictor_NN of_IN atherosclerotic_JJ vascular_NN disease_NN ,_, a_DT major_JJ clinical_JJ consequence_NN of_IN insulin_NN
        resistance_NN [_NN 10_CD ]_NN ._. Hence_RB ,_, the_DT interrelationships_NNS between_IN obesity_NN ,_, insulin_NN resistance_NN ,_, and_CC
        atherosclerosis_NNS are_VBP of_IN great_JJ scientific_JJ and_CC clinical_JJ interest_NN ._.
        We_PRP originally_RB identified_VBD and_CC characterized_VBN resistin_NN as_IN a_DT circulating_VBG mouse_NN adipocyte_NN
        gene_NN product_NN that_WDT is_VBZ regulated_VBN by_IN antidiabetic_JJ drugs_NNS [_NN 11_CD ]_NN ._. In_IN rodents_NNS ,_, resistin_NN is_VBZ derived_VBN
        exclusively_RB from_IN adipocytes_NNS [_NN 11_CD ,_, 12_CD ]_NN ,_, circulates_NNS at_IN increased_VBN levels_NNS in_IN obese_NN animals_NNS [_NN 11_CD ]_NN ,_,
        and_CC causes_NNS dysregulated_JJ hepatic_JJ glucose_NN production_NN ,_, leading_VBG to_TO insulin_NN resistance_NN [_NN 13_CD ,_, 14_CD ]_NN ._.
        A_DT syntenic_JJ gene_NN exists_VBZ in_IN humans_NNS ,_, but_CC is_VBZ expressed_VBN at_IN higher_JJR levels_NNS in_IN monocytes_NNS and_CC
        macrophages_NNS than_IN in_IN adipocytes_NNS [_NN 15_CD ,_, 16_CD ]_NN ,_, raising_VBG questions_NNS about_IN the_DT relationship_NN between_IN
        resistin_NN and_CC human_JJ metabolic_JJ disease_NN ._. Recently_RB ,_, several_JJ studies_NNS have_VBP suggested_VBN that_IN
        metabolic_JJ abnormalities_NNS are_VBP associated_VBN with_IN polymorphisms_NNS in_IN the_DT human_JJ resistin_NN gene_NN
        [_NN 17_CD ,_, 18_CD ]_NN ._. Furthermore_RB ,_, several_JJ studies_NNS ,_, though_IN not_RB all_DT ,_, have_VBP reported_VBN increased_VBN serum_NN
        resistin_NN levels_NNS in_IN patients_NNS with_IN obesity_NN ,_, insulin_NN resistance_NN ,_, and_CC /_NN or_CC type_NN 2_CD diabetes_NN
        [_NN 19_CD ,_, 20_CD ,_, 21_CD ,_, 22_CD ,_, 23_CD ,_, 24_CD ,_, 25_CD ,_, 26_CD ]_NN ._. However_RB ,_, the_DT mechanism_NN and_CC importance_NN of_IN increased_VBN resistin_NN
        levels_NNS in_IN human_JJ metabolic_JJ disease_NN are_VBP not_RB known_VBN ._.
        Here_RB we_PRP show_VBP that_IN the_DT endotoxin_NN lipopolysaccharide_NN (_( LPS_NNP )_) ,_, a_DT potent_JJ inflammatory_JJ
        stimulant_NN ,_, dramatically_RB increases_VBZ resistin_NN production_NN by_IN inducing_VBG secretion_NN of_IN inflammatory_JJ
        cytokines_NNS such_JJ as_IN TNFα_NNP ._. This_DT increase_NN in_IN resistin_NN production_NN is_VBZ blocked_VBN by_IN both_DT aspirin_NN and_CC
        rosiglitazone_NN ,_, drugs_NNS that_WDT have_VBP dual_JJ anti-inflammatory_JJ and_CC insulin-sensitizing_JJ actions_NNS and_CC
        have_VBP been_VBN shown_VBN to_TO antagonize_VB NF-κB_NNP ._. Indeed_RB ,_, activation_NN of_IN NF-κB_NNP is_VBZ sufficient_JJ to_TO induce_VB
        resistin_NN expression_NN ,_, and_CC loss_NN of_IN NF-κB_NNP function_NN abolishes_NNS LPS_NNP induction_NN of_IN resistin_NN ._.
        Resistin_NNP serum_NN levels_NNS are_VBP increased_VBN dramatically_RB by_IN endotoxemia_NN in_IN humans_NNS ,_, and_CC correlate_VBP
        with_IN a_DT marker_NN of_IN inflammation_NN in_IN patients_NNS with_IN type_NN 2_CD diabetes_NN ._. Thus_RB ,_, systemic_JJ inflammation_NN
        leads_VBZ to_TO increased_VB resistin_NN production_NN and_CC circulating_VBG levels_NNS in_IN humans_NNS ._. The_DT increased_VBN
        level_NN of_IN resistin_NN in_IN humans_NNS with_IN obesity_NN is_VBZ likely_JJ an_DT indirect_JJ result_NN of_IN elevated_VBD levels_NNS of_IN
        inflammatory_JJ cytokines_NNS characteristic_NN of_IN states_NNS of_IN increased_VBN adiposity_NN ._. Hence_RB ,_, obesity_NN and_CC
        acute_JJ inflammation_NN are_VBP both_DT hyperresistinemic_JJ states_NNS associated_VBN with_IN insulin_NN
        resistance_NN ._.
      
      
        Methods_NNP
        
          Differentiation_NNP of_IN Primary_JJ Human_NNP Macrophages_NNP
          Peripheral_NNP blood_NN mononuclear_NN cells_NNS were_VBD isolated_VBN from_IN whole_JJ blood_NN of_IN healthy_JJ donors_NNS
          following_VBG apheresis_NNS and_CC elutriation_NN ._. Greater_NNP than_IN 90_CD %_NN of_IN these_DT monocytes_NNS expressed_VBD CD_NNP 14_CD
          and_CC HLA-DR_NNP ._. Cells_NNP were_VBD plated_JJ in_IN 24_CD -_: well_RB plates_NNS at_IN a_DT density_NN of_IN 10_CD
          6_CD cells_NNS per_IN well_RB ,_, allowed_VBN to_TO adhere_VB for_IN 4_CD h_NN ,_, then_RB washed_VBN with_IN
          Dulbecco_NNP 's_POS Modified_NNP Eagles_NNPS Medium_NNP and_CC further_JJ cultured_JJ in_IN 10_CD %_NN FBS_NNP in_IN Dulbecco_NNP 's_POS Modified_NNP
          Eagles_NNPS Medium_NNP supplemented_JJ with_IN 5_CD ng_NN /_NN ml_NN GM-CSF_NNP (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, Missouri_NNP ,_, United_NNP
          States_NNPS )_) to_TO promote_VB macrophage_NN differentiation_NN ._. All_DT experiments_NNS were_VBD performed_VBN after_IN
          overnight_JJ equilibration_NN with_IN macrophage_NN serum-free_JJ medium_NN (_( GIBCO_NNP ,_, San_NNP Diego_NNP ,_, California_NNP ,_,
          United_NNP States_NNPS ;_: Invitrogen_NNP ,_, Carlsbad_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) supplemented_JJ with_IN 5_CD ng_NN /_NN ml_NN
          GM-CSF_NNP ._. Cells_NNP were_VBD treated_VBN with_IN LPS_NNP (_( Sigma_NNP )_) ,_, aspirin_NN (_( Sigma_NNP )_) ,_, SN_NNP 50_CD ,_, and_CC /_NN or_CC control_NN
          peptide_NN (_( Biomol_NNP ,_, Plymouth_NNP Meeting_VBG ,_, Pennsylvania_NNP ,_, United_NNP States_NNPS )_) ,_, MG_NNP 132_CD ,_, PD_NNP 98059_CD ,_, SB_NNP 20358_CD
          (_( Calbiochem_NNP ,_, San_NNP Diego_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ,_, and_CC TNFα_NNP (_( R_NN &_CC D_NNP Systems_NNPS ,_,
          Minneapolis_NNP ,_, Minnesota_NNP ,_, United_NNP States_NNPS )_) ._. Neutralizing_NNP antibodies_NNS to_TO TNFα_NNP ,_, IL-_NNP 6_CD ,_, and_CC
          anti-_NN IL-_NNP 1_CD β_NN ,_, as_RB well_RB as_IN control_NN IgG_NNP ,_, were_VBD obtained_VBN from_IN R_NN &_CC D_NNP Systems_NNPS ._. Adenovirus_NNP
          expressing_VBG activated_VBN IKK_NNP in_IN pAD_NN easy_JJ with_IN GFP_NNP and_CC control_NN vector_NN was_VBD a_DT generous_JJ gift_NN from_IN
          Steven_NNP Shoelson_NNP ._.
        
        
          RNA_NNP Isolation_NNP and_CC Quantification_NNP
          RNA_NNP was_VBD isolated_VBN using_VBG RNeasy_NNP Mini_NNP Kit_NNP (_( Qiagen_NNP ,_, Valencia_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ,_,
          then_RB subjected_VBN to_TO DNase_NNP digestion_NN followed_VBN by_IN reverse_NN transcription_NN (_( Invitrogen_NNP )_) ._. mRNA_NN
          transcripts_NNS were_VBD quantified_VBN by_IN the_DT dual-labeled_JJ fluorogenic_JJ probe_NN method_NN for_IN real-time_JJ
          PCR_NNP ,_, using_VBG a_DT Prism_NNP 7900_CD thermal_JJ cycler_NN and_CC sequence_NN detector_NN (_( Applied_NNP Biosystems_NNP ,_, Foster_NNP
          City_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ._. Real-time_NNP PCR_NNP was_VBD performed_VBN using_VBG Taqman_NNP Universal_NNP
          Polymerase_NNP Master_NNP Mix_NNP (_( Applied_NNP Biosystems_NNP )_) ._. The_DT primers_NNS and_CC probes_NNS used_VBN in_IN the_DT real-time_JJ
          PCR_NNP were_VBD the_DT following_VBG :_: Sense-_NNP Resistin_NNP ,_, 5_CD ′_NN -_: AGCCATCAATGATAGGATCCA-_NNP 3_CD ′_NN ;_: Antisense-_NNP Resistin_NNP ,_,
          5_CD ′_NN -_: TCCAGGCCAATGCTGCTTAT-_NNP 3_CD ′_NN ;_: Resistin_NNP Probe_NNP ,_, 5_CD ′_NN -_: Fam-_NNP
          AGGTCGCCGGCTCCCTAATATTTAGGG-TAMRA-_NNP 3_CD ′_NN ;_: Sense_NN human_JJ 36_CD B_NNP 4_CD sense_NN ,_, 5_CD ′_NN -_:
          TCGTGGAAGTGACATCGTCTTT-_NNP 3_CD ′_NN ;_: Antisense_NNP 36_CD B_NNP 4_CD ,_, 5_CD ′_NN -_: CTGTCTTCCCTGGGCATCA-_NNP 3_CD ′_NN ;_: and_CC 36_CD B_NNP 4_CD Probe_NNP ,_,
          5_CD ′_NN -_: FAM-_NNP TGGCAATCCCTGACGCACCG-TAMRA-_NNP 3_CD ′_NN ._.
          Primer_NNP and_CC probe_NN for_IN TNFα_NNP were_VBD obtained_VBN from_IN Applied_NNP Biosystems_NNP ._. The_DT cycle_NN number_NN at_IN
          which_WDT the_DT transcripts_NNS of_IN the_DT gene_NN of_IN interest_NN were_VBD detectable_JJ (_( CT_NNP )_) was_VBD normalized_JJ to_TO the_DT
          cycle_NN number_NN of_IN 36_CD B_NNP 4_CD detection_NN ,_, referred_VBD to_TO as_IN deltaCT_NN ._. The_DT fold_VB change_NN in_IN expression_NN of_IN
          the_DT gene_NN of_IN interest_NN in_IN the_DT compound-treated_JJ group_NN relative_JJ to_TO that_DT in_IN the_DT
          vehicle-treated_JJ group_NN was_VBD expressed_VBN as_IN 2_CD
          −_NN deltadeltaCT_NN ,_, in_IN which_WDT deltadeltaCT_NN equals_VBZ the_DT deltaCT_NN of_IN the_DT
          compound-treated_JJ group_NN minus_CC the_DT deltaCT_NN of_IN the_DT chosen_VBN control_NN group_NN ,_, which_WDT was_VBD
          normalized_JJ to_TO 1_CD ._.
        
        
          ELISA_NNP
          Resistin_NNP concentrations_NNS ,_, in_IN cell_NN media_NNS and_CC human_JJ plasma_NN ,_, were_VBD assessed_VBN with_IN a_DT
          commercially_RB available_JJ ELISA_NNP (_( Linco_NNP Research_NNP ,_, St_NNP ._. Charles_NNP ,_, Missouri_NNP ,_, United_NNP States_NNPS )_) and_CC
          normalized_JJ to_TO cell_NN protein_NN ._. The_DT average_JJ correlation_NN coefficient_NN for_IN standards_NNS using_VBG a_DT
          four-parameter_JJ fit_NN was_VBD 0_CD ._. 99_CD ._. Intra-assay_NNP and_CC inter-assay_JJ coefficients_NNS of_IN variance_NN were_VBD
          4_CD ._. 7_CD %_NN and_CC 9_CD ._. 1_CD %_NN ,_, respectively_RB ._. Direct_JJ comparison_NN of_IN standard_JJ curves_NNS generated_VBN by_IN the_DT Linco_NNP
          kit_NN with_IN those_DT yielded_VBN by_IN another_DT commercially_RB available_JJ resistin_NN ELISA_NNP (_( Biovendor_NNP
          Laboratory_NNP Medicine_NNP ,_, Brno_NNP ,_, Czech_NNP Republic_NNP )_) yielded_VBD high_JJ correlation_NN (_( rho_NN =_SYM 0_CD ._. 99_CD ,_, 
          p_NN <_NN 0_CD ._. 001_CD )_) ,_, except_IN that_IN the_DT Biovendor_NNP values_NNS were_VBD approximately_RB 30_CD %_NN
          lower_JJR than_IN those_DT determined_VBN with_IN the_DT Linco_NNP assay_NN ._. This_DT appeared_VBD to_TO be_VB related_VBN to_TO the_DT
          standards_NNS used_VBN for_IN calibration_NN ._. Discrepant_NNP absolute_JJ values_NNS among_IN different_JJ assays_NNS ,_,
          including_VBG the_DT Biovendor_NNP assay_NN ,_, were_VBD recently_RB described_VBN by_IN others_NNS [_NN 22_CD ]_NN ._. Resistin_NNP levels_NNS in_IN
          40_CD plasma_NN samples_NNS were_VBD measured_VBN using_VBG both_DT Linco_NNP and_CC Biovendor_NNP ELISA_NNP kits_NNS ,_, with_IN moderate_JJ
          correlation_NN (_( rho_NN =_SYM 0_CD ._. 66_CD )_) ._. Levels_NNP of_IN soluble_JJ TNFα_NNP receptor_NN 2_CD (_( sTNFR_NN 2_LS )_) were_VBD measured_VBN using_VBG
          a_DT commercially_RB available_JJ immunoassay_NN (_( R_NN &_CC D_NNP Systems_NNPS )_) ._. Intra-assay_NNP and_CC inter-assay_JJ
          coefficients_NNS of_IN variance_NN were_VBD 5_CD ._. 1_CD %_NN and_CC 9_CD ._. 8_CD %_NN ,_, respectively_RB ._.
        
        
          Human_NNP Endotoxemia_NNP Study_NNP
          Healthy_JJ volunteers_NNS (_(
          n_NN =_SYM 6_CD ,_, three_CD male_JJ and_CC three_CD female_JJ )_) ,_, aged_VBN 18_CD –_NN 45_CD y_NN with_IN BMI_NNP between_IN 20_CD
          and_CC 30_CD and_CC on_IN no_DT medications_NNS ,_, were_VBD studied_VBN ._. The_DT University_NNP of_IN Pennsylvania_NNP Institutional_NNP
          Review_NNP Board_NNP approved_VBD the_DT study_NN protocol_NN ,_, and_CC all_DT participants_NNS gave_VBD written_VBN informed_VBN
          consent_NN ._. Following_VBG screening_NN and_CC exclusion_NN of_IN individuals_NNS with_IN any_DT clinical_JJ or_CC laboratory_NN
          abnormalities_NNS ,_, participants_NNS were_VBD admitted_VBN to_TO the_DT General_NNP Clinical_NNP Research_NNP Center_NNP at_IN the_DT
          University_NNP of_IN Pennsylvania_NNP for_IN a_DT 60_CD h_NN stay_NN ._. Serial_JJ blood_NN samples_NNS were_VBD collected_VBN during_IN
          the_DT 24_CD h_NN prior_RB to_TO and_CC 24_CD h_NN following_VBG the_DT intravenous_JJ administration_NN of_IN
          human-research-grade_JJ endotoxin_NN (_( obtained_VBN from_IN National_NNP Institutes_NNPS of_IN Health_NNP Clinical_NNP
          Center_NNP ,_, reference_NN endotoxin_NN [_NN CCRE_NNP ]_NN [_NN lots_NNS 1_CD and_CC 2_CD ;_: National_NNP Institutes_NNPS of_IN Health_NNP Clinical_NNP
          Center_NNP PDS_NNP #_# 67801_CD ]_NN )_) at_IN a_DT dose_NN of_IN 3_CD ng_NN /_NN kg_NN given_VBN at_IN 6_CD AM_NNP ._. Plasma_NNP and_CC whole_JJ blood_NN RNA_NNP (_( PAX_NNP
          tube_NN isolators_NNS ,_, Qiagen_NNP )_) samples_NNS were_VBD isolated_VBN from_IN blood_NN ,_, and_CC stored_VBD under_IN appropriate_JJ
          conditions_NNS for_IN subsequent_JJ assays_NNS ._.
        
        
          Type_NNP 2_CD Diabetes_NNP Study_NNP
          Participants_NNS with_IN type_NN 2_CD diabetes_NN (_(
          n_NN =_SYM 215_CD ,_, 167_CD male_JJ and_CC 48_CD female_JJ )_) ,_, aged_VBN 35_CD –_NN 75_CD y_NN and_CC free_JJ from_IN clinical_JJ
          cardiovascular_JJ diseases_NNS ,_, were_VBD recruited_VBN through_IN the_DT diabetes_NN clinics_NNS at_IN the_DT University_NNP of_IN
          Pennsylvania_NNP Medical_NNP Center_NNP and_CC the_DT Veterans_NNP Affairs_NNPS Medical_NNP Center_NNP ,_, Philadelphia_NNP ,_,
          Pennsylvania_NNP ,_, to_TO an_DT ongoing_JJ study_NN of_IN cardiovascular_JJ risk_NN factors_NNS in_IN type_NN 2_CD diabetes_NN ._. The_DT
          sample_NN was_VBD composed_VBN of_IN 59_CD %_NN Caucasians_NNP and_CC 35_CD %_NN African-_NNP Americans_NNPS ._. All_DT participants_NNS were_VBD
          evaluated_VBN at_IN the_DT University_NNP of_IN Pennsylvania_NNP General_NNP Clinical_NNP Research_NNP Center_NNP in_IN a_DT fasting_VBG
          state_NN at_IN 8_CD AM_NNP ._. The_DT University_NNP of_IN Pennsylvania_NNP Institutional_NNP Review_NNP Board_NNP approved_VBD the_DT
          study_NN protocol_NN ,_, and_CC all_DT participants_NNS gave_VBD written_VBN informed_VBN consent_NN ._. The_DT patient_NN
          population_NN is_VBZ described_VBN in_IN more_JJR detail_NN elsewhere_RB [_NN 27_CD ]_NN ._.
        
        
          Statistical_NNP Methods_NNP
          Data_NNP are_VBP reported_VBN as_IN mean_NN and_CC standard_JJ error_NN of_IN the_DT mean_NN (_( SEM_NNP )_) for_IN continuous_JJ
          variables_NNS ._. Because_IN of_IN baseline_NN variation_NN in_IN cell_NN populations_NNS between_IN batches_NNS of_IN primary_JJ
          human_JJ monocytes_NNS isolated_VBN from_IN multiple_JJ donors_NNS ,_, cell_NN culture_NN experiments_NNS were_VBD performed_VBN in_IN
          triplicate_NN and_CC data_NNS from_IN representative_NN experiments_NNS are_VBP presented_VBN ._. For_IN cell_NN culture_NN
          experiments_NNS with_IN multiple_JJ treatments_NNS ,_, analysis_NN of_IN variance_NN (_( ANOVA_NNP )_) was_VBD used_VBN to_TO test_VB for_IN
          differences_NNS in_IN means_VBZ across_IN treatment_NN groups_NNS ._. When_WRB significant_JJ global_JJ differences_NNS were_VBD
          found_VBN ,_, post_NN hoc_FW 
          t_NN -_: tests_NNS were_VBD used_VBN to_TO compare_VB specific_JJ treatment_NN groups_NNS to_TO the_DT control_NN ._.
          Data_NNS from_IN the_DT human_JJ endotoxemia_NN experiment_NN were_VBD analyzed_VBN by_IN repeated_VBN measures_NNS ANOVA_NNP ._. In_IN
          the_DT type_NN 2_CD diabetes_NN study_NN ,_, Spearman_NNP correlations_NNS of_IN plasma_NN levels_NNS of_IN resistin_NN with_IN plasma_NN
          sTNFR_NN 2_CD levels_NNS are_VBP presented_VBN ._.
        
      
      
        Results_NNS
        
          Induction_NNP of_IN Resistin_NNP Gene_NNP and_CC Protein_NNP Expression_NNP by_IN Endotoxin_NNP Treatment_NNP of_IN Human_NNP
          Macrophages_NNP
          The_DT regulation_NN of_IN resistin_NN expression_NN was_VBD studied_VBN in_IN primary_JJ cultures_NNS of_IN human_JJ
          monocytic_JJ cells_NNS ._. Immediately_RB upon_IN plating_VBG of_IN elutriated_JJ primary_JJ human_JJ monocytes_NNS ,_, resistin_NN
          gene_NN expression_NN was_VBD detectable_JJ but_CC highly_RB variable_JJ from_IN experiment_NN to_TO experiment_NN (_( data_NNS
          not_RB shown_VBN )_) ._. One_CD day_NN after_IN plating_VBG ,_, resistin_NN gene_NN expression_NN remained_VBD detectable_JJ at_IN low_JJ
          levels_NNS (_( Figure_NN 1_CD A_DT )_) ._. Subjection_NNP of_IN the_DT cells_NNS to_TO a_DT protocol_NN leading_VBG to_TO differentiation_NN
          along_IN the_DT macrophage_NN lineage_NN led_VBN to_TO a_DT modest_JJ ,_, time-dependent_JJ enhancement_NN of_IN resistin_NN gene_NN
          expression_NN (_( Figure_NN 1_CD A_DT )_) ._. In_IN agreement_NN with_IN a_DT previous_JJ report_NN [_NN 28_CD ]_NN ,_, treatment_NN of_IN primary_JJ
          macrophages_NNS with_IN the_DT endotoxin_NN LPS_NNP led_VBD to_TO a_DT dramatic_JJ ,_, dose-responsive_JJ increase_NN in_IN
          resistin_NN gene_NN expression_NN (_( Figure_NN 1_CD B_NNP )_) ._. We_PRP also_RB determined_VBD that_IN this_DT effect_NN of_IN LPS_NNP was_VBD
          paralleled_JJ by_IN an_DT increase_NN in_IN resistin_NN protein_NN secretion_NN into_IN the_DT medium_NN (_( Figure_NN 1_CD C_NNP )_) ._. Of_IN
          note_NN ,_, activated_VBN mouse_NN peritoneal_JJ macrophages_NNS harvested_VBN after_IN thioglycolate_NN treatment_NN did_VBD
          not_RB express_VB detectable_JJ levels_NNS of_IN mouse_NN resistin_NN ,_, even_RB after_IN treatment_NN with_IN LPS_NNP (_( data_NNS not_RB
          shown_VBN )_) ._.
        
        
          Endotoxin_NNP Induction_NNP of_IN Resistin_NNP Is_VBZ Delayed_JJ with_IN Respect_NN to_TO TNFα_NNP
          Induction_NNP of_IN resistin_NN gene_NN expression_NN by_IN LPS_NNP exposure_NN of_IN human_JJ macrophages_NNS began_VBD
          between_IN 6_CD and_CC 24_CD h_NN after_IN treatment_NN ,_, with_IN peak_NN expression_NN at_IN 24_CD h_NN (_( Figure_NN 2_CD A_DT )_) ._. This_DT time_NN
          course_NN of_IN resistin_NN induction_NN was_VBD delayed_VBN relative_JJ to_TO induction_NN of_IN TNFα_NNP gene_NN expression_NN ,_,
          which_WDT was_VBD detectable_JJ at_IN 2_CD h_NN and_CC peaked_VBD 6_CD h_NN after_IN LPS_NNP exposure_NN (_( Figure_NN 2_CD B_NNP )_) ._. The_DT secretion_NN
          of_IN TNFα_NNP followed_VBD a_DT similar_JJ time_NN course_NN (_( Figure_NN 2_CD C_NNP )_) ._. By_IN contrast_NN ,_, secretion_NN of_IN resistin_NN
          did_VBD not_RB increase_VB until_IN much_JJ later_RB ,_, more_RBR closely_RB following_VBG the_DT pattern_NN of_IN the_DT appearance_NN
          of_IN sTNFR_NN 2_CD ,_, a_DT marker_NN of_IN TNFα_NNP action_NN (_( Figure_NN 2_CD C_NNP )_) [_NN 29_CD ]_NN ._.
        
        
          Endotoxin_NNP Induction_NNP of_IN Resistin_NNP Is_VBZ Blocked_VBN by_IN Immunoneutralization_NNP of_IN Multiple_NNP
          Cytokines_NNP
          Resistin_NNP gene_NN expression_NN was_VBD also_RB induced_VBN by_IN TNFα_NNP treatment_NN of_IN primary_JJ human_JJ
          macrophages_NNS (_( Figure_NN 3_CD A_DT )_) [_NN 28_CD ]_NN ,_, and_CC resistin_NN secretion_NN increased_VBD in_IN parallel_JJ (_( Figure_NN 3_CD B_NNP )_) ._.
          Since_IN LPS_NNP induction_NN of_IN TNFα_NNP preceded_VBN the_DT increase_NN in_IN resistin_NN (_( see_VB Figure_NN 2_CD C_NNP )_) ,_, we_PRP
          hypothesized_VBN that_IN TNFα_NNP ,_, or_CC a_DT similar_JJ cytokine_NN produced_VBD early_RB after_IN LPS_NNP exposure_NN ,_, was_VBD
          responsible_JJ for_IN the_DT later_JJ induction_NN of_IN resistin_NN ._. Indeed_RB ,_, neutralizing_VBG antibodies_NNS to_TO TNFα_NNP
          markedly_RB attenuated_JJ the_DT increase_NN in_IN resistin_NN gene_NN expression_NN (_( Figure_NN 3_CD C_NNP )_) ._. LPS_NNP treatment_NN
          also_RB induces_VBZ other_JJ cytokines_NNS ,_, including_VBG IL-_NNP 6_CD and_CC IL-_NNP 1_CD β_NN [_NN 30_CD ]_NN ,_, and_CC IL-_NNP 6_CD induces_VBZ resistin_NN
          modestly_RB (_( data_NNS not_RB shown_VBN )_) [_NN 28_CD ]_NN ._. Antibodies_NNP to_TO IL-_NNP 6_CD and_CC IL-_NNP 1_CD β_NN individually_RB had_VBD minor_JJ
          effects_NNS on_IN LPS_NNP stimulation_NN of_IN resistin_NN (_( Figure_NN 3_CD C_NNP )_) ._. However_RB ,_, the_DT combination_NN of_IN
          antibodies_NNS to_TO TNFα_NNP ,_, IL-_NNP 6_CD ,_, and_CC IL-_NNP 1_CD β_NN markedly_RB attenuated_JJ LPS_NNP induction_NN of_IN resistin_NN (_( Figure_NN
          3_CD C_NNP )_) ._. These_DT data_NNS clearly_RB show_VBP that_DT resistin_NN induction_NN by_IN endotoxin_NN is_VBZ mediated_JJ by_IN a_DT
          cascade_NN in_IN which_WDT the_DT primary_JJ event_NN is_VBZ secretion_NN of_IN inflammatory_JJ cytokines_NNS that_IN ,_, in_IN turn_NN ,_,
          induce_VB resistin_NN ._.
        
        
          Induction_NNP of_IN Resistin_NNP Is_VBZ Blocked_VBN by_IN Anti-_NNP Inflammatory_NNP Insulin-_NNP Sensitizing_NNP Drugs_NNPS
          That_DT Target_NNP NF-κB_NNP
          Mouse_NNP resistin_NN ,_, produced_VBD exclusively_RB by_IN adipocytes_NNS ,_, is_VBZ down-regulated_JJ by_IN antidiabetic_JJ
          thiazolidinediones_NNS ,_, including_VBG rosiglitazone_NN [_NN 11_CD ]_NN ._. Consistent_NNP with_IN an_DT earlier_JJR report_NN [_NN 16_CD ]_NN ,_,
          rosiglitazone_NN down-regulated_JJ resistin_NN gene_NN expression_NN (_( Figure_NN 4_CD A_DT )_) in_IN LPS-stimulated_NNP human_JJ
          macrophages_NNS ._. Resistin_NNP protein_NN secretion_NN was_VBD also_RB significantly_RB reduced_VBN by_IN rosiglitazone_NN
          (_( Figure_NN 4_CD B_NNP )_) ._. Hence_RB ,_, macrophage_NN expression_NN of_IN resistin_NN and_CC its_PRP$ induction_NN by_IN LPS_NNP is_VBZ
          species-specific_JJ ,_, but_CC down-regulation_JJ of_IN resistin_NN by_IN thiazolidinedione_NN occurs_VBZ both_DT in_IN
          rodents_NNS and_CC humans_NNS ._. Rosiglitazone_NNP has_VBZ marked_VBN anti-inflammatory_JJ effects_NNS on_IN macrophages_NNS
          [_NN 31_CD ]_NN ._. This_DT led_VBN us_PRP to_TO examine_VB the_DT effect_NN of_IN aspirin_NN ,_, an_DT anti-inflammatory_JJ compound_NN that_IN
          targets_NNS IκB_NNP kinase_NN and_CC has_VBZ insulin-sensitizing_JJ effects_NNS [_NN 32_CD ]_NN ._. Remarkably_NNP ,_, aspirin_NN
          dramatically_RB decreased_VBD endotoxin-induced_JJ resistin_NN expression_NN in_IN a_DT dose-dependent_JJ manner_NN
          (_( Figure_NN 4_CD C_NNP )_) ._. Both_DT aspirin_NN (_( via_IN IκB_NNP kinase_NN )_) and_CC rosiglitazone_NN (_( via_IN PPARγ_NNP )_) inhibit_VB NF-κB_NNP
          [_NN 31_CD ,_, 32_CD ]_NN ,_, which_WDT is_VBZ activated_VBN by_IN LPS_NNP ._. Indeed_RB ,_, treatment_NN of_IN the_DT macrophages_NNS with_IN the_DT
          proteasome_NN inhibitor_NN MG_NNP 132_CD ,_, which_WDT prevents_VBZ NF-κB_NNP activation_NN [_NN 33_CD ]_NN ,_, abrogated_JJ
          endotoxin-induced_JJ activation_NN of_IN resistin_NN expression_NN (_( data_NNS not_RB shown_VBN )_) ._. Moreover_RB ,_, treatment_NN
          of_IN the_DT macrophages_NNS with_IN SN_NNP 50_CD ,_, a_DT cell-permeable_JJ peptide_NN that_WDT specifically_RB prevents_VBZ
          activation_NN of_IN NF-κB_NNP by_IN inhibiting_VBG its_PRP$ nuclear_JJ translocation_NN [_NN 34_CD ]_NN ,_, nearly_RB abolished_VBN
          endotoxin-induced_JJ activation_NN of_IN resistin_NN expression_NN (_( Figure_NN 4_CD D_NNP )_) ._. Thus_RB ,_, activation_NN of_IN
          NF-κB_NNP is_VBZ required_VBN for_IN LPS_NNP induction_NN of_IN resistin_NN in_IN human_JJ macrophages_NNS ._. Furthermore_RB ,_,
          constitutive_JJ activation_NN of_IN NF-κB_NNP by_IN adenoviral_NN expression_NN of_IN activated_VBN IκB_NNP kinase_NN was_VBD
          sufficient_JJ to_TO induce_VB resistin_NN in_IN primary_JJ human_JJ macrophages_NNS (_( Figure_NN 4_CD E_NNP )_) ._. The_DT magnitude_NN of_IN
          this_DT activation_NN was_VBD less_JJR than_IN that_DT caused_VBN by_IN LPS_NNP ,_, which_WDT is_VBZ known_VBN to_TO also_RB activate_VBP
          MAP-kinase_NNP (_( MAPK_NNP )_) ._. Indeed_RB ,_, inhibition_NN of_IN either_DT p_NN 42_CD MAPK_NNP by_IN PD_NNP 98059_CD ,_, or_CC p_NN 38_CD MAPK_NNP (_( using_VBG
          SB_NNP 20358_CD )_) partially_RB blocked_VBD the_DT induction_NN of_IN resistin_NN by_IN LPS_NNP (_( Figure_NN 4_CD F_NN )_) ._. Together_RB these_DT
          results_NNS show_VBP that_IN NF-κB_NNP activation_NN is_VBZ necessary_JJ and_CC sufficient_JJ for_IN resistin_NN induction_NN by_IN
          LPS_NNP ,_, with_IN MAPK_NNP activation_NN increasing_VBG the_DT magnitude_NN of_IN the_DT response_NN ._.
        
        
          LPS_NNP Robustly_NNP Increases_NNS Circulating_NNP Resistin_NNP Levels_NNP in_IN Healthy_JJ Humans_NNP
          Next_JJ ,_, we_PRP asked_VBD whether_IN our_PRP$ findings_NNS from_IN ex_FW vivo_NN studies_NNS of_IN human_JJ macrophages_NNS would_MD
          translate_VB into_IN in_IN vivo_NN observations_NNS in_IN humans_NNS ._. Six_CD healthy_JJ volunteers_NNS were_VBD injected_VBN with_IN
          LPS_NNP ,_, using_VBG a_DT protocol_NN similar_JJ to_TO that_DT shown_VBN to_TO produce_VB insulin_NN resistance_NN [_NN 35_CD ]_NN ._. Baseline_NNP
          circulating_VBG resistin_NN levels_NNS were_VBD approximately_RB 4_CD ng_NN /_NN ml_NN ,_, and_CC remained_VBD relatively_RB constant_JJ
          for_IN several_JJ hours_NNS prior_RB to_TO LPS_NNP infusion_NN (_( Figure_NN 5_CD A_DT )_) ._. Remarkably_NNP ,_, resistin_NN levels_NNS rose_VBD
          dramatically_RB because_IN of_IN endotoxemia_NN ,_, peaking_VBG 8_CD –_NN 16_CD h_NN after_IN LPS_NNP administration_NN (_( Figure_NN 5_CD A_DT )_) ._.
          The_DT time_NN course_NN of_IN hyperresistinemia_NN paralleled_JJ the_DT increase_NN in_IN circulating_VBG levels_NNS of_IN
          sTNFR_NN 2_CD ,_, although_IN the_DT increase_NN in_IN resistin_NN levels_NNS was_VBD more_JJR marked_VBD and_CC sustained_VBN (_( Figure_NN
          5_CD A_DT )_) ._. The_DT increase_NN in_IN resistin_NN protein_NN levels_NNS correlated_JJ with_IN increased_VBN resistin_NN gene_NN
          expression_NN in_IN peripheral_JJ blood_NN mononuclear_NN cells_NNS following_VBG systemic_JJ endotoxemia_NN (_( Figure_NN
          5_CD B_NNP )_) ._.
        
        
          Circulating_NNP Resistin_NNP Levels_NNP Correlate_NNP with_IN the_DT Inflammatory_NNP Marker_NNP sTNFR_NN 2_CD in_IN
          Patients_NNPS with_IN Type_NNP 2_CD Diabetes_NNP
          Patients_NNS with_IN type_NN 2_CD diabetes_NN and_CC insulin_NN resistance_NN ,_, many_DT of_IN whom_WP are_VBP obese_NN ,_, have_VBP
          elevated_VBD levels_NNS of_IN several_JJ inflammatory_JJ markers_NNS ,_, including_VBG IL-_NNP 6_CD ,_, TNFα_NNP ,_, and_CC sTNFR_NN 2_CD [_NN 36_CD ]_NN ._.
          LPS_NNP administration_NN has_VBZ been_VBN shown_VBN to_TO induce_VB acute_JJ insulin_NN resistance_NN in_IN humans_NNS [_NN 37_CD ]_NN ._.
          Given_VBN that_IN LPS_NNP infusion_NN increased_VBD resistin_NN levels_NNS ,_, we_PRP measured_VBD resistin_NN in_IN a_DT cohort_NN of_IN
          215_CD patients_NNS with_IN type_NN 2_CD diabetes_NN ._. Circulating_NNP resistin_NN levels_NNS were_VBD significantly_RB
          correlated_JJ with_IN levels_NNS of_IN sTNFR_NN (_( Figure_NN 6_CD A_DT )_) ._. Thus_RB ,_, there_EX is_VBZ an_DT association_NN between_IN
          resistin_NN levels_NNS and_CC systemic_JJ inflammation_NN in_IN patients_NNS with_IN type_NN 2_CD diabetes_NN ._.
        
      
      
        Discussion_NNP
        We_PRP have_VBP demonstrated_VBN that_IN ,_, in_IN human_JJ macrophages_NNS ,_, an_DT inflammatory_JJ cascade_NN with_IN secretion_NN
        of_IN cytokines_NNS ,_, including_VBG TNFα_NNP and_CC IL-_NNP 6_CD ,_, is_VBZ sufficient_JJ and_CC necessary_JJ for_IN the_DT induction_NN of_IN
        resistin_NN ._. Insulin_NNP sensitizers_NNS that_WDT have_VBP anti-inflammatory_JJ properties_NNS ,_, including_VBG a_DT synthetic_JJ
        PPARγ_NNP agonist_NN as_RB well_RB as_IN aspirin_NN ,_, suppress_VB macrophage_NN resistin_NN expression_NN ,_, as_IN does_VBZ direct_JJ
        inhibition_NN of_IN NF-κB_NNP ._. Experimental_NNP endotoxemia_NN in_IN healthy_JJ volunteers_NNS ,_, based_VBN on_IN the_DT
        well-established_JJ gram-negative_JJ bacterial_JJ inflammatory_JJ response_NN in_IN humans_NNS [_NN 38_CD ,_, 39_CD ,_, 40_CD ]_NN ,_,
        induces_VBZ a_DT dramatic_JJ elevation_NN of_IN circulating_VBG resistin_NN levels_NNS ._. Hence_RB ,_, resistin_NN gene_NN and_CC
        protein_NN expression_NN are_VBP increased_VBN by_IN inflammatory_JJ stimuli_NNS both_DT ex_FW vivo_NN and_CC in_IN vivo_NN ._.
        In_IN rodents_NNS ,_, resistin_NN is_VBZ produced_VBN exclusively_RB by_IN adipocytes_NNS ,_, regulates_VBZ normal_JJ glucose_NN
        homeostasis_NNS ,_, and_CC causes_NNS insulin_NN resistance_NN at_IN high_JJ circulating_VBG levels_NNS [_NN 11_CD ,_, 13_CD ]_NN ._. Translation_NN
        of_IN resistin_NN 's_POS metabolic_JJ effects_NNS from_IN rodents_NNS to_TO humans_NNS has_VBZ been_VBN problematic_JJ because_IN
        peripheral_JJ blood_NN mononuclear_NN cells_NNS and_CC macrophages_NNS appear_VBP to_TO be_VB a_DT primary_JJ source_NN of_IN
        resistin_NN in_IN humans_NNS [_NN 15_CD ,_, 16_CD ]_NN ._. This_DT species_NNS difference_NN in_IN primary_JJ locus_JJ of_IN expression_NN is_VBZ yet_RB
        another_DT example_NN of_IN the_DT close_NN and_CC functionally_RB overlapping_VBG relationship_NN between_IN adipocytes_NNS
        and_CC macrophages_NNS [_NN 41_CD ]_NN ._. Numerous_JJ studies_NNS have_VBP reported_VBN that_IN circulating_VBG resistin_NN levels_NNS are_VBP
        increased_VBN in_IN human_JJ obesity_NN [_NN 20_CD ,_, 25_CD ,_, 26_CD ,_, 41_CD ]_NN and_CC diabetes_NN [_NN 19_CD ,_, 20_CD ,_, 23_CD ,_, 42_CD ,_, 43_CD ]_NN ._. Our_PRP$ data_NNS suggest_VBP
        that_IN ,_, whereas_IN hyperresistinemia_NN in_IN obese_NN rodents_NNS derives_VBZ directly_RB from_IN adipocytes_NNS ,_, human_JJ
        resistin_NN is_VBZ indirectly_RB regulated_VBN by_IN the_DT inflammatory_JJ internal_JJ milieu_NN of_IN obesity_NN (_( Figure_NN
        6_CD B_NNP )_) ._. Indeed_RB ,_, obesity_NN is_VBZ associated_VBN with_IN elevated_VBD levels_NNS of_IN cytokines_NNS whose_WP$ systemic_JJ
        administration_NN leads_VBZ to_TO impaired_VBN glucose_NN homeostasis_NNS [_NN 36_CD ,_, 44_CD ,_, 45_CD ]_NN ,_, such_JJ as_IN TNFα_NNP and_CC IL-_NNP 6_CD ,_,
        which_WDT we_PRP show_VBP here_RB to_TO mediate_VB the_DT inflammatory_JJ induction_NN of_IN human_JJ resistin_NN ._. Thus_RB ,_, in_IN both_DT
        species_NNS ,_, adipose_NN tissue_NN is_VBZ an_DT endocrine_NN organ_NN containing_VBG adipocytes_NNS as_RB well_RB as_IN macrophages_NNS
        that_WDT regulates_VBZ energy_NN metabolism_NN and_CC glucose_NN homeostasis_NNS through_IN secretion_NN of_IN multiple_JJ
        factors_NNS ,_, including_VBG inflammatory_JJ cytokines_NNS [_NN 46_CD ]_NN ._.
        Clearly_RB the_DT relationship_NN between_IN obesity_NN ,_, inflammation_NN ,_, and_CC resistin_NN expression_NN is_VBZ
        complex_JJ ,_, and_CC needs_VBZ to_TO be_VB systematically_RB studied_VBN in_IN larger_JJR and_CC varied_VBD patient_NN populations_NNS ._.
        Intriguingly_NNP ,_, we_PRP found_VBD a_DT strong_JJ correlation_NN between_IN plasma_NN levels_NNS of_IN resistin_NN and_CC sTNFR_NN 2_CD ,_,
        the_DT soluble_JJ cleavage_NN product_NN of_IN the_DT activated_VBN TNFα_NNP receptor_NN ,_, in_IN diabetic_JJ patients_NNS ._. A_DT
        comparable_JJ correlation_NN between_IN resistin_NN and_CC sTNFR_NN 2_CD (_(
        R_NN =_SYM 0_CD ._. 31_CD ,_, 
        p_NN <_NN 0_CD ._. 001_CD )_) was_VBD found_VBN in_IN a_DT cohort_NN of_IN 879_CD non-diabetic_JJ individuals_NNS ,_, in_IN
        whom_WP resistin_NN levels_NNS independently_RB correlated_JJ with_IN coronary_JJ atherosclerotic_JJ disease_NN (_( M_NNP ._. P_NN ._.
        Reilly_NNP ,_, M_NNP ._. Lehrke_NNP ,_, M_NNP ._. L_NNP ._. Wolfe_NNP ,_, A_DT ._. Rohatgi_NNP ,_, M_NNP ._. A_DT ._. Lazar_NNP ,_, and_CC D_NNP ._. J_NNP ._. Rader_NNP ,_, unpublished_JJ
        data_NNS )_) ._.
        LPS_NNP binds_NNS to_TO pathogen-associated-molecular-pattern_JJ innate_JJ immune_JJ receptors_NNS ,_, such_JJ as_IN CD_NNP 14_CD
        and_CC Toll-like_NNP receptor_NN 4_CD ,_, activating_VBG signal_NN cascades_NNS involving_VBG NF-κB_NNP and_CC MAPK_NNP [_NN 47_CD ]_NN and_CC
        thereby_RB inducing_VBG the_DT transcription_NN and_CC secretion_NN of_IN early_JJ cytokines_NNS ,_, including_VBG TNFα_NNP and_CC
        IL-_NNP 1_CD [_NN 48_CD ]_NN ._. We_PRP have_VBP shown_VBN here_RB that_IN these_DT early_JJ cytokines_NNS are_VBP responsible_JJ for_IN secondary_JJ
        induction_NN or_CC enhancement_NN of_IN resistin_NN expression_NN in_IN macrophages_NNS ._. Hyperresistinemia_NNP impairs_NNS
        glucose_NN homeostasis_NNS in_IN rodents_NNS [_NN 49_CD ,_, 50_CD ]_NN ,_, and_CC inflammatory_JJ states_NNS are_VBP associated_VBN with_IN insulin_NN
        resistance_NN [_NN 36_CD ]_NN ,_, which_WDT may_MD serve_VB as_IN a_DT physiological_JJ attempt_NN to_TO increase_VB the_DT provision_NN of_IN
        glucose_NN to_TO the_DT brain_NN under_IN stress_NN conditions_NNS ._. Indeed_RB ,_, induction_NN of_IN acute_JJ inflammation_NN by_IN
        administration_NN of_IN LPS_NNP causes_NNS insulin_NN resistance_NN in_IN humans_NNS [_NN 37_CD ]_NN ,_, and_CC here_RB we_PRP have_VBP
        demonstrated_VBN the_DT concomitant_NN induction_NN of_IN resistin_NN ._. Interestingly_RB ,_, the_DT peak_NN in_IN TNFα_NNP and_CC
        IL-_NNP 6_CD levels_NNS after_IN LPS_NNP administration_NN to_TO humans_NNS precedes_VBZ a_DT phase_NN of_IN prolonged_JJ insulin_NN
        resistance_NN that_WDT begins_VBZ approximately_RB 6_CD h_NN after_IN LPS_NNP administration_NN [_NN 37_CD ]_NN ,_, closely_RB
        approximating_VBG the_DT time_NN course_NN of_IN resistin_NN induction_NN ._. Hence_RB resistin_NN is_VBZ a_DT potential_JJ mediator_NN
        of_IN insulin_NN resistance_NN in_IN humans_NNS with_IN acute_JJ inflammation_NN ._. Moreover_RB ,_, obesity_NN is_VBZ associated_VBN
        with_IN activation_NN of_IN innate_JJ immunity_NN [_NN 6_CD ]_NN ,_, including_VBG the_DT inflammatory_JJ mediators_NNS that_WDT induce_VB
        resistin_NN ._. In_IN this_DT context_NN it_PRP is_VBZ intriguing_JJ that_IN resistin_NN levels_NNS are_VBP increased_VBN in_IN obesity_NN
        [_NN 25_CD ,_, 26_CD ]_NN and_CC that_IN insulin-sensitizing_JJ agents_NNS such_JJ as_IN aspirin_NN and_CC rosiglitazone_NN ,_, with_IN
        disparate_JJ primary_JJ molecular_JJ targets_NNS ,_, antagonize_VB resistin_NN induction_NN ._. Indeed_RB ,_,
        thiazolidinedione_NN suppression_NN of_IN resistin_NN levels_NNS has_VBZ recently_RB been_VBN correlated_JJ with_IN hepatic_JJ
        insulin_NN sensitization_NN [_NN 43_CD ]_NN ._. Future_JJ work_NN will_MD be_VB needed_VBN to_TO better_RB understand_VB the_DT
        relationship_NN between_IN circulating_VBG resistin_NN levels_NNS and_CC the_DT insulin_NN resistance_NN characteristic_NN
        of_IN inflammatory_JJ states_NNS ,_, including_VBG obesity_NN ._.
      
    
  
